Clinical Trial

Australian Genomics Of Chronic Allograft Dysfunction Study

Study acronym: AUSCAD
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of the Australian Genomics of Chronic Allograft Dysfunction (AUSCAD) study is a single centre (Westmead Hospital), prospective, observational study, which enrols patients at time of kidney (or kidney-transplant) transplant and tracks the post transplant course. The AUSCAD study aims to generate new knowledge and improve outcomes following kidney transplantation. The primary aim is to determine whether important outcomes (including chronic rejection and graft loss) are correlated with patterns of allograft reactivity, gene expression and susceptibility profiles.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-03-10; most recent amendment 2025-07-14.
Trial Details
NCT Number NCT06314230
Lead Sponsor Western Sydney Local Health District
Conditions Kidney Transplant Rejection, Kidney Transplant; Complications
Enrollment 500 participants
Start Date 2012-04-26
Primary Completion 2040-01-01 (estimated)
Study Completion 2040-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-17